Details of Disease

General Information of Disease (ID: DISMN944)

• Disease Name: Myeloid leukaemia
• Synonyms: myeloid granulocytic leukemia; myelocytic leukemia; leukaemia myelogenous; leukemia, granulocytic, malignant; non-lymphocytic leukemia; leukaemia granulocytic; myelogenous leukaemia; myelocytic leukaemia; leukaemia myeloid; non-lymphocytic leukaemia; leukemia myeloid; myeloid granulocytic leukaemia; non-lymphoblastic leukaemia; myeloid leukemia; myelogenous leukemia; leukemia granulocytic; non-lymphoblastic leukemia; leukemia myelogenous
• Disease Class: 2B33: Malignant haematopoietic neoplasm
• Definition: A clonal proliferation of myeloid cells and their precursors in the bone marrow, peripheral blood, and spleen. When the proliferating cells are immature myeloid cells and myeloblasts, it is called acute myeloid leukemia. When the proliferating myeloid cells are neutrophils, it is called chronic myelogenous leukemia.
• Disease Hierarchy:
  DISNAKFL: Leukemia
  DIS5KAPA: Myeloproliferative neoplasm
  DISMN944: Myeloid leukaemia
• ICD Code:
  ICD-11: ICD-11: 2B33.1
  ICD-9: ICD-9: 208.9
  Expand ICD-11: '2B33.1
  Expand ICD-10: 'C92; 'C92.9; 'C93; 'C93.7; 'C93.9
  Expand ICD-9: 208.9
• Disease Identifiers:
  MONDO ID: MONDO_0004643
  MESH ID: D007951
  UMLS CUI: C0023470
  MedGen ID: 7320
  HPO ID: HP:0012324
  SNOMED CT ID: 1163439000

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Lestaurtinib	DMQ2AIJ	Approved (orphan drug)	Small molecular drug	[1]
Mycophenolate mofetil	DMPQAGE	Approved	Small molecular drug	[2]
Mycophenolic acid	DMRBMAU	Approved	NA	[3]

This Disease is Treated as An Indication in 8 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Combined PR1/WT1 vaccine	DMGCTX5	Phase 2	Vaccine	[4]
LR3001	DMZQBCL	Phase 2	Antisense drug	[6]
Anti-CD33 CAR-T cells	DM9NPF6	Phase 1/2	CAR T Cell Therapy	[7]
CART33 cells	DM81JIT	Phase 1/2	CAR T Cell Therapy	[8]
Allogeneic CART-33	DM4RHM5	Phase 1	CAR T Cell Therapy	[9]
AMG 319	DM9P0NA	Phase 1	NA	[10]
BAY2402234	DMRL6W5	Phase 1	NA	[11]
CD19.CAR-aNKT cells	DMMO2EJ	Phase 1	CAR T Cell Therapy	[12]

This Disease is Treated as An Indication in 1 Drugs in Phase 2 Trial

Drug Name	Drug ID	Highest Status	Drug Type	REF
Cyclosporin A	DMUYKBZ	Phase 2 Trial	Small molecular drug	[5]

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
GSK'963	DMNOU59	Investigative	Small molecular drug	[13]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 43 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
BCL11A	TTR61MW	Limited	Biomarker	[14]
DNMT3A	TTJUALD	Limited	Genetic Variation	[15]
IL11	TTGUYTR	Limited	Altered Expression	[16]
IL2RB	TT9721Y	Limited	Biomarker	[17]
JAK3	TTT7PJU	Limited	Genetic Variation	[18]
MYB	TT8V13P	Limited	Biomarker	[19]
NQO1	TT8XK6L	Limited	Genetic Variation	[20]
PAX5	TTA4REJ	Limited	Genetic Variation	[21]
PSIP1	TTH9LDP	Limited	Biomarker	[17]
PSMB6	TT8EPLT	Limited	Genetic Variation	[22]
TCF3	TTULOD8	Limited	Biomarker	[17]
DLL1	TT9CFQD	Disputed	Biomarker	[23]
IL24	TT1EPXZ	Disputed	Biomarker	[24]
IRF8	TTHUBNK	Disputed	Altered Expression	[25]
PRTN3	TT5MLC4	Disputed	Biomarker	[26]
CD33	TTJVYO3	moderate	Biomarker	[27]
HDAC2	TTSHTOI	moderate	Biomarker	[28]
KMT2A	TT1GNDM	moderate	Biomarker	[29]
RARA	TTW38KT	moderate	Biomarker	[30]
ABL1	TT6B75U	Strong	Biomarker	[31]
ABL2	TT1A6HL	Strong	Biomarker	[32]
ATG2B	TTG6KCU	Strong	Biomarker	[33]
BCAT1	TTES57P	Strong	Biomarker	[34]
CCR7	TT2GIDQ	Strong	Altered Expression	[35]
CD6	TTMF6KC	Strong	Biomarker	[36]
CTAG1A	TTE5ITK	Strong	Altered Expression	[37]
FDXR	TT3W4IX	Strong	Biomarker	[38]
FECH	TTQ6VF4	Strong	Genetic Variation	[39]
FES	TTLBY21	Strong	Altered Expression	[40]
FLT3	TTGJCWZ	Strong	Altered Expression	[41]
HEXIM1	TTFOKAH	Strong	Biomarker	[42]
HOXA11	TTEX4ZA	Strong	Genetic Variation	[43]
HOXA13	TTN26OM	Strong	Genetic Variation	[43]
IL3RA	TTENHJ0	Strong	Altered Expression	[44]
LMO2	TTFX379	Strong	Altered Expression	[45]
MSI2	TTTXQF6	Strong	Biomarker	[46]
NCAM1	TTVXPHT	Strong	Biomarker	[47]
OLFM4	TTK1CX7	Strong	Biomarker	[48]
P2RX1	TTJW7B3	Strong	Biomarker	[49]
TOP2B	TT4NVEM	Strong	Therapeutic	[50]
YWHAH	TTADIOY	Strong	Posttranslational Modification	[51]
RUNX1	TTWIN3H	Definitive	Genetic Variation	[52]
TNFRSF8	TT2GM5R	Definitive	Altered Expression	[53]

This Disease Is Related to 107 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CAMK2G	OTHD9KJG	Limited	Biomarker	[54]
CUX1	OTU1LCNJ	Limited	Biomarker	[17]
HCLS1	OTX7WGYN	Limited	Biomarker	[17]
IL17RB	OT0KDNSF	Limited	Biomarker	[55]
KHSRP	OTDHZARB	Limited	Biomarker	[17]
KRT31	OTB6RCAH	Limited	Posttranslational Modification	[56]
NMU	OTW9X7BQ	Limited	Altered Expression	[57]
PBX1	OTORABGO	Limited	Biomarker	[58]
PICALM	OTQVRPMQ	Limited	Genetic Variation	[59]
PPP1R3A	OTJL9VYP	Limited	Biomarker	[60]
PRAM1	OTZN3DWD	Limited	Altered Expression	[61]
PRDM16	OT0BGA27	Limited	Altered Expression	[62]
PTTG1	OTIMYS4W	Limited	Biomarker	[63]
RBM15	OT8ZPGWF	Limited	Genetic Variation	[64]
SIGLEC7	OTNDLURR	Limited	Biomarker	[17]
SPI1	OTVCA1D0	Limited	Altered Expression	[65]
ASXL1	OTX931AW	Disputed	Genetic Variation	[66]
MLLT10	OTURMDV7	Disputed	Biomarker	[59]
AGO2	OT4JY32Q	moderate	Altered Expression	[28]
ETV6	OTCZMG61	moderate	Biomarker	[67]
IL3	OT0CQ35N	moderate	Biomarker	[68]
KMT2E	OTYOLNOG	moderate	Biomarker	[69]
MEIS1	OTH9DKAD	moderate	Biomarker	[70]
NUP98	OTNT12G2	moderate	Genetic Variation	[71]
SETBP1	OTKGCOSR	moderate	Biomarker	[72]
ADA2	OTGCV24S	Strong	Biomarker	[73]
AFDN	OTTRU341	Strong	Biomarker	[74]
BASP1	OTF4VS5G	Strong	Altered Expression	[75]
BCR	OTCN76C1	Strong	Altered Expression	[76]
CBFB	OTIAC6W4	Strong	Biomarker	[77]
CBX1	OT2L4XZX	Strong	Altered Expression	[78]
CBX3	OTOP9RLD	Strong	Altered Expression	[78]
CCDC28A	OTSWUMXT	Strong	Biomarker	[79]
CDC23	OTC4O83E	Strong	Biomarker	[80]
CLIC4	OT6KTPKD	Strong	Biomarker	[81]
CMTM5	OTMS7NDP	Strong	Biomarker	[82]
CTAG1B	OTIQGW6U	Strong	Altered Expression	[37]
CTDSPL	OTZJ0CZK	Strong	Altered Expression	[83]
DACH1	OTMKNAGG	Strong	Altered Expression	[84]
DERL1	OTJUS74N	Strong	Genetic Variation	[85]
DUSP7	OT6Z5AHP	Strong	Altered Expression	[86]
EIF4G2	OTEO98CR	Strong	Biomarker	[87]
ERG	OTOTX9VU	Strong	Altered Expression	[88]
EVPL	OTZIAFEK	Strong	Altered Expression	[89]
FANCB	OTMZTXB5	Strong	Biomarker	[90]
FBXW11	OT2A6RLR	Strong	Biomarker	[91]
FIP1L1	OTF91GTL	Strong	Biomarker	[92]
FOXH1	OTEXJ9SL	Strong	Biomarker	[93]
FUBP1	OT77SC9N	Strong	Biomarker	[94]
GATA1	OTX1R7O1	Strong	Biomarker	[84]
GATA2	OTBP2QQ2	Strong	Biomarker	[95]
GFI1B	OTRDW8YO	Strong	Biomarker	[96]
GSKIP	OTEYSV5M	Strong	Biomarker	[33]
GUCA1B	OT85S0J3	Strong	Biomarker	[97]
HBG1	OTVL4NSU	Strong	Biomarker	[98]
HBG2	OT4J48JJ	Strong	Biomarker	[98]
HOXA9	OTKNK5H0	Strong	Altered Expression	[84]
HOXC4	OT52VJ6V	Strong	Altered Expression	[99]
HOXC5	OTPQTLKZ	Strong	Altered Expression	[99]
HOXC6	OTBCRAZV	Strong	Altered Expression	[99]
HTN1	OTH3W1RR	Strong	Biomarker	[42]
HTN3	OTEUXA81	Strong	Biomarker	[42]
IQCG	OTIX9V3E	Strong	Genetic Variation	[71]
KDM3B	OTZU5J5S	Strong	Biomarker	[100]
KIF20A	OTXOQHE0	Strong	Biomarker	[101]
L3MBTL1	OT8M52QY	Strong	Biomarker	[102]
LARGE1	OTUH7H9F	Strong	Biomarker	[103]
MAGEB2	OTAGUVU5	Strong	Altered Expression	[37]
MECOM	OTP983W8	Strong	Altered Expression	[35]
MEF2C	OTZGF1Y5	Strong	Altered Expression	[104]
MLLT1	OT41UZU5	Strong	Biomarker	[105]
MN1	OTVQR4R9	Strong	Biomarker	[106]
MNX1	OTXP9FH1	Strong	Altered Expression	[107]
MOS	OTNMQPFJ	Strong	Genetic Variation	[108]
MYH11	OTVNVWY3	Strong	Biomarker	[109]
NELL2	OTS4MJZ7	Strong	Altered Expression	[110]
NRBP1	OTRWEJ65	Strong	Posttranslational Modification	[51]
NUP214	OTWEA19O	Strong	Biomarker	[111]
ORC5	OTFPW8DE	Strong	Genetic Variation	[112]
OSCP1	OTZ4IFGJ	Strong	Altered Expression	[113]
P2RX2	OT0LF34A	Strong	Biomarker	[49]
P2RX6	OT1FNTXA	Strong	Biomarker	[49]
PIK3C2A	OTFBU4GD	Strong	Biomarker	[114]
PLEKHG2	OTMGR6I6	Strong	Altered Expression	[115]
PLSCR1	OTGY9B5T	Strong	Altered Expression	[116]
PRDX2	OTLWCY9T	Strong	Therapeutic	[50]
PRKD2	OTIFSVI8	Strong	Altered Expression	[117]
PRRX1	OTTZK5G8	Strong	Biomarker	[70]
RAD21	OTQS84ZF	Strong	Biomarker	[118]
RERE	OT3G4GBZ	Strong	Biomarker	[32]
SCYL1	OTQ0IN7P	Strong	Altered Expression	[119]
SKI	OT4KJ8F6	Strong	Altered Expression	[120]
SMC1A	OT9ZMRK9	Strong	Biomarker	[118]
SMC3	OTWGFRHD	Strong	Biomarker	[118]
SMR3B	OTL5HNM8	Strong	Biomarker	[121]
SNAP91	OTE3EXWZ	Strong	Genetic Variation	[59]
STAG2	OTR6X1Q7	Strong	Biomarker	[118]
STAT2	OTO9G2RZ	Strong	Biomarker	[122]
SYCP3	OTKOF54H	Strong	Altered Expression	[83]
SYNCRIP	OTRNDZXB	Strong	Biomarker	[123]
TBC1D9	OTSSCTB5	Strong	Genetic Variation	[124]
TLE4	OT4QEH6T	Strong	Biomarker	[125]
BSPH1	OTLLM5JY	Definitive	Biomarker	[126]
METTL3	OTSXP1M3	Definitive	Biomarker	[127]
QRSL1	OTJDU2UG	Definitive	Biomarker	[128]
RUNX1T1	OT30DED5	Definitive	Genetic Variation	[52]
SMARCD2	OTQTBWHW	Definitive	Biomarker	[129]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5672).
• [2] Mycophenolate mofetil FDA Label
• [3] Mycophenolic Acid overcomes imatinib and nilotinib resistance of chronic myeloid leukemia cells by apoptosis or a senescent-like cell cycle arrest. Leuk Res Treatment. 2012;2012:861301.
• [4] Review of the Results of WT1 Peptide Vaccination Strategies for Myelodysplastic Syndromes and Acute Myeloid Leukemia from Nine Different Studies. Front Immunol. 2015 Feb 4;6:36.
• [5] Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2024 Feb;11(2):e127-e135.
• [6] Pipeline report of Genta.
• [7] ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
• [8] ClinicalTrials.gov (NCT01864902) Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33
• [9] ClinicalTrials.gov (NCT02799680) Allogeneic CART-33 for Relapsed/Refractory CD33+ AML
• [10] ClinicalTrials.gov (NCT01300026) AMG 319 Lymphoid Malignancy FIH. U.S. National Institutes of Health.
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] ClinicalTrials.gov (NCT03774654) CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)
• [13] Characterization of GSK'963: a structurally distinct, potent and selective inhibitor of RIP1 kinase. Cell Death Discov. 2015 Jul 27;1:15009.
• [14] Evi9 encodes a novel zinc finger protein that physically interacts with BCL6, a known human B-cell proto-oncogene product.Mol Cell Biol. 2000 May;20(9):3178-86. doi: 10.1128/MCB.20.9.3178-3186.2000.
• [15] DNMT3A Loss Drives Enhancer Hypomethylation in FLT3-ITD-Associated Leukemias.Cancer Cell. 2016 Jun 13;29(6):922-934. doi: 10.1016/j.ccell.2016.05.003.
• [16] Molecular cloning of two isoforms of a receptor for the human hematopoietic cytokine interleukin-11.Blood. 1995 Oct 1;86(7):2534-40.
• [17] Proteolytic processing of cut homeobox 1 by neutrophil elastase in the MV4;11 myeloid leukemia cell line.Mol Cancer Res. 2008 Apr;6(4):644-53. doi: 10.1158/1541-7786.MCR-07-0268.
• [18] Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.J Biol Chem. 2015 Nov 27;290(48):29022-34. doi: 10.1074/jbc.M115.670224. Epub 2015 Oct 7.
• [19] Peptidomimetic blockade of MYB in acute myeloid leukemia.Nat Commun. 2018 Jan 9;9(1):110. doi: 10.1038/s41467-017-02618-6.
• [20] NAD(P)H:quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a HuGE review.Genet Med. 2002 Mar-Apr;4(2):62-70. doi: 10.1097/00125817-200203000-00003.
• [21] Expression of B cell-specific activator protein/PAX5 in acute myeloid leukemia with t(8;21)(q22;q22).Am J Clin Pathol. 2006 Aug;126(2):235-40. doi: 10.1309/LG0Q-0VXY-BETJ-4VHE.
• [22] Ras point mutations occur in acute myeloid leukemia with illegitimate T-cell receptor delta gene rearrangement.Leukemia. 1994 Jan;8(1):102-5.
• [23] Cellular analysis of growth suppression induced by the Notch ligands, Delta-1 and Jagged-1 in two myeloid leukemia cell lines.Int J Mol Med. 2004 Aug;14(2):223-6.
• [24] Immunogenicity moderation effect of interleukin-24 on myelogenous leukemia cells.Anticancer Drugs. 2018 Apr;29(4):353-363. doi: 10.1097/CAD.0000000000000606.
• [25] Bcr-abl regulates Stat5 through Shp2, the interferon consensus sequence binding protein (Icsbp/Irf8), growth arrest specific 2 (Gas2) and calpain.Oncotarget. 2016 Nov 22;7(47):77635-77650. doi: 10.18632/oncotarget.12749.
• [26] Proteinase 3, Wegener's autoantigen: from gene to antigen.J Leukoc Biol. 2001 Feb;69(2):177-90.
• [27] Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies.Haematologica. 2007 Mar;92(3):381-8. doi: 10.3324/haematol.10873.
• [28] Knock-down of argonaute 2 (AGO2) induces apoptosis in myeloid leukaemia cells and inhibits siRNA-mediated silencing of transfected oncogenes in HEK-293 cells.Basic Clin Pharmacol Toxicol. 2011 Oct;109(4):274-82. doi: 10.1111/j.1742-7843.2011.00716.x. Epub 2011 May 31.
• [29] ZFX modulates the growth of human leukemic cells via B4GALT1.Acta Biochim Biophys Sin (Shanghai). 2016 Dec;48(12):1120-1127. doi: 10.1093/abbs/gmw109. Epub 2016 Oct 26.
• [30] Neutrophil elastase enhances the proliferation and decreases apoptosis of leukemia cells via activation of PI3K/Akt signaling.Mol Med Rep. 2016 May;13(5):4175-82. doi: 10.3892/mmr.2016.5051. Epub 2016 Mar 28.
• [31] The malignancy suppression role of miR-23a by targeting the BCR/ABL oncogene in chromic myeloid leukemia.Cancer Gene Ther. 2014 Sep;21(9):397-404. doi: 10.1038/cgt.2014.44. Epub 2014 Sep 12.
• [32] Constitutively active ABL family kinases, TEL/ABL and TEL/ARG, harbor distinct leukemogenic activities in vivo.Leukemia. 2017 Dec;31(12):2742-2751. doi: 10.1038/leu.2017.114. Epub 2017 Apr 7.
• [33] Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies.Nat Genet. 2015 Oct;47(10):1131-40. doi: 10.1038/ng.3380. Epub 2015 Aug 17.
• [34] Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia.Nature. 2017 May 25;545(7655):500-504. doi: 10.1038/nature22314. Epub 2017 May 17.
• [35] Prominent Oncogenic Roles of EVI1 in Breast Carcinoma.Cancer Res. 2017 Apr 15;77(8):2148-2160. doi: 10.1158/0008-5472.CAN-16-0593. Epub 2017 Feb 16.
• [36] MN1-TEL, the product of the t(12;22) in human myeloid leukemia, immortalizes murine myeloid cells and causes myeloid malignancy in mice.Leukemia. 2006 Sep;20(9):1582-92. doi: 10.1038/sj.leu.2404298. Epub 2006 Jun 29.
• [37] The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leuk Res. 2010 Jul;34(7):899-905. doi: 10.1016/j.leukres.2010.02.004. Epub 2010 Apr 10.
• [38] Tuberostemonine reverses multidrug resistance in chronic myelogenous leukemia cells K562/ADR.J Cancer. 2017 Apr 9;8(6):1103-1112. doi: 10.7150/jca.17688. eCollection 2017.
• [39] Erythropoietic protoporphyria: altered phenotype after bone marrow transplantation for myelogenous leukemia in a patient heteroallelic for ferrochelatase gene mutations.J Am Acad Dermatol. 2002 Jun;46(6):861-6. doi: 10.1067/mjd.2002.120460.
• [40] Expression of c-Fes protein isoforms correlates with differentiation in myeloid leukemias.DNA Cell Biol. 2005 May;24(5):311-6. doi: 10.1089/dna.2005.24.311.
• [41] RNA binding protein MSI2 positively regulates FLT3 expression in myeloid leukemia.Leuk Res. 2017 Mar;54:47-54. doi: 10.1016/j.leukres.2017.01.015. Epub 2017 Jan 11.
• [42] His-1 and His-2: identification and chromosomal mapping of two commonly rearranged sites of viral integration in a myeloid leukemia.Oncogene. 1991 Nov;6(11):2041-7.
• [43] Single-translocation and double-chimeric transcripts: detection of NUP98-HOXA9 in myeloid leukemias with HOXA11 or HOXA13 breaks of the chromosomal translocation t(7;11)(p15;p15).Blood. 2002 Feb 15;99(4):1428-33. doi: 10.1182/blood.v99.4.1428.
• [44] High CD123 levels enhance proliferation in response to IL-3, but reduce chemotaxis by downregulating CXCR4 expression.Blood Adv. 2017 Jun 20;1(15):1067-1079. doi: 10.1182/bloodadvances.2016002931. eCollection 2017 Jun 27.
• [45] The expression of LMO2 protein in acute B-cell and myeloid leukemia.Hematology. 2010 Jun;15(3):132-4. doi: 10.1179/102453309X12583347113618.
• [46] Musashi 2 contributes to the stemness and chemoresistance of liver cancer stem cells via LIN28A activation.Cancer Lett. 2017 Jan 1;384:50-59. doi: 10.1016/j.canlet.2016.10.007. Epub 2016 Oct 6.
• [47] CD56-positive adult T-cell leukemia/lymphoma: a case report and a review of the literature.Med Mol Morphol. 2015 Mar;48(1):54-9. doi: 10.1007/s00795-014-0072-1. Epub 2014 Mar 28.
• [48] Olfactomedin 4 is a novel target gene of retinoic acids and 5-aza-2'-deoxycytidine involved in human myeloid leukemia cell growth, differentiation,... Blood. 2010 Dec 2;116(23):4938-47.
• [49] Chronic treatment with P2-purinergic receptor agonists induces phenotypic modulation of the HL-60 and U937 human myelogenous leukemia cell lines.J Leukoc Biol. 1991 Aug;50(2):109-22. doi: 10.1002/jlb.50.2.109.
• [50] Downregulation of topoisomerase IIbeta in myeloid leukemia cell lines leads to activation of apoptosis following all-trans retinoic acid-induced differentiation/growth arrest. Leukemia. 2006 Oct;20(10):1809-18. doi: 10.1038/sj.leu.2404351. Epub 2006 Aug 17.
• [51] MADM, a novel adaptor protein that mediates phosphorylation of the 14-3-3 binding site of myeloid leukemia factor 1.J Biol Chem. 2002 Oct 25;277(43):40997-1008. doi: 10.1074/jbc.M206041200. Epub 2002 Aug 9.
• [52] Acute myeloid leukemia with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1 and KIT Exon 8 mutation is associated with characteristic mastocytosis and dismal outcomes.Exp Mol Pathol. 2019 Jun;108:131-136. doi: 10.1016/j.yexmp.2019.04.009. Epub 2019 Apr 17.
• [53] CD30 Expression Is Rare in Myeloid Leukemia Cutis: A Study of 55 Cases and Implications for Routine Diagnostic Algorithms.Am J Dermatopathol. 2017 May;39(5):351-357. doi: 10.1097/DAD.0000000000000755.
• [54] Activated Ca2+/calmodulin-dependent protein kinase IIgamma is a critical regulator of myeloid leukemia cell proliferation.Cancer Res. 2008 May 15;68(10):3733-42. doi: 10.1158/0008-5472.CAN-07-2509.
• [55] IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1.J Biol Chem. 2001 Jan 12;276(2):1660-4. doi: 10.1074/jbc.M008289200.
• [56] Investigation of methylation at Hha I sites using the hypervariable probe M27 beta allows improved clonal analysis in myeloid leukaemia and demonstrates differences in methylation between leukaemic and remission samples.Leukemia. 1994 Jan;8(1):190-4.
• [57] Neuromedin U: a Myb-regulated autocrine growth factor for human myeloid leukemias.Blood. 2004 Sep 15;104(6):1833-40. doi: 10.1182/blood-2003-10-3577. Epub 2004 Jun 8.
• [58] EB-1, a tyrosine kinase signal transduction gene, is transcriptionally activated in the t(1;19) subset of pre-B ALL, which express oncoprotein E2a-Pbx1.Oncogene. 1999 Sep 2;18(35):4920-9. doi: 10.1038/sj.onc.1202874.
• [59] CALM-AF10 is a common fusion transcript in T-ALL and is specific to the TCRgammadelta lineage.Blood. 2003 Aug 1;102(3):1000-6. doi: 10.1182/blood-2002-09-2913. Epub 2003 Apr 3.
• [60] Alterations of the PPP1R3 gene in hematological malignancies.Int J Oncol. 2000 Oct;17(4):717-21. doi: 10.3892/ijo.17.4.717.
• [61] A case of acute eosinophilic granulocytic leukemia with PML-RAR alpha fusion gene expression and response to all-trans retinoic acid.Leukemia. 1997 Apr;11(4):609-11. doi: 10.1038/sj.leu.2400600.
• [62] Overexpression of sPRDM16 coupled with loss of p53 induces myeloid leukemias in mice.J Clin Invest. 2007 Dec;117(12):3696-707. doi: 10.1172/JCI32390.
• [63] Inflammation regulates long non-coding RNA-PTTG1-1:1 in myeloid leukemia.Haematologica. 2020 Jun;105(6):e280-e284. doi: 10.3324/haematol.2019.217281. Epub 2019 Oct 3.
• [64] Hemophagocytosis by leukemic megakaryoblasts in acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13);RBM15-MKL1.J Pediatr Hematol Oncol. 2012 Oct;34(7):576-80. doi: 10.1097/MPH.0b013e318245a027.
• [65] Sox4 cooperates with PU.1 haploinsufficiency in murine myeloid leukemia.Blood. 2011 Oct 27;118(17):4674-81. doi: 10.1182/blood-2011-04-351528. Epub 2011 Aug 30.
• [66] Asxl1 deficiency in embryonic fibroblasts leads to cellular senescence via impairment of the AKT-E2F pathway and Ezh2 inactivation.Sci Rep. 2017 Jul 12;7(1):5198. doi: 10.1038/s41598-017-05564-x.
• [67] Microdeletion del(22)(q12.2) encompassing the facial development-associated gene, MN1 (meningioma 1) in a child with Pierre-Robin sequence (including cleft palate) and neurofibromatosis 2 (NF2): a case report and review of the literature.BMC Med Genet. 2012 Mar 22;13:19. doi: 10.1186/1471-2350-13-19.
• [68] Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.BioDrugs. 2009;23(1):1-13. doi: 10.2165/00063030-200923010-00001.
• [69] Loss of MLL5 results in pleiotropic hematopoietic defects, reduced neutrophil immune function, and extreme sensitivity to DNA demethylation.Blood. 2009 Feb 12;113(7):1432-43. doi: 10.1182/blood-2008-06-162263. Epub 2008 Oct 14.
• [70] Leukemogenic properties of NUP98-PMX1 are linked to NUP98 and homeodomain sequence functions but not to binding properties of PMX1 to serum response factor.Oncogene. 2008 Oct 9;27(46):6056-67. doi: 10.1038/onc.2008.210. Epub 2008 Jul 7.
• [71] A new fusion gene NUP98-IQCG identified in an acute T-lymphoid/myeloid leukemia with a t(3;11)(q29q13;p15)del(3)(q29) translocation.Oncogene. 2008 May 29;27(24):3414-23. doi: 10.1038/sj.onc.1210999. Epub 2007 Dec 17.
• [72] Somatic SETBP1 mutations in myeloid malignancies.Nat Genet. 2013 Aug;45(8):942-6. doi: 10.1038/ng.2696. Epub 2013 Jul 7.
• [73] Systematic identification of genes involved in metabolic acid stress resistance in yeast and their potential as cancer targets.Dis Model Mech. 2016 Sep 1;9(9):1039-49. doi: 10.1242/dmm.023374. Epub 2016 Aug 12.
• [74] MLL-AF6 fusion oncogene sequesters AF6 into the nucleus to trigger RAS activation in myeloid leukemia.Blood. 2014 Jul 10;124(2):263-72. doi: 10.1182/blood-2013-09-525741. Epub 2014 Apr 2.
• [75] WT1 and its transcriptional cofactor BASP1 redirect the differentiation pathway of an established blood cell line.Biochem J. 2011 Apr 1;435(1):113-25. doi: 10.1042/BJ20101734.
• [76] Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias.Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):10002-7. doi: 10.1073/pnas.1633833100. Epub 2003 Jul 30.
• [77] Coexistence of p210(BCR-ABL) and CBF-MYH11 fusion genes in myeloid leukemia: A report of 4 cases.Oncol Lett. 2017 Nov;14(5):5171-5178. doi: 10.3892/ol.2017.6812. Epub 2017 Aug 24.
• [78] Granulocyte maturation determines ability to release chromatin NETs and loss of DNA damage response; these properties are absent in immature AML granulocytes.Biochim Biophys Acta. 2013 Mar;1833(3):767-79. doi: 10.1016/j.bbamcr.2012.12.012. Epub 2012 Dec 23.
• [79] Characterization of 6q abnormalities in childhood acute myeloid leukemia and identification of a novel t(6;11)(q24.1;p15.5) resulting in a NUP98-C6orf80 fusion in a case of acute megakaryoblastic leukemia.Genes Chromosomes Cancer. 2005 Nov;44(3):225-32. doi: 10.1002/gcc.20233.
• [80] Human CDC23: cDNA cloning, mapping to 5q31, genomic structure, and evaluation as a candidate tumor suppressor gene in myeloid leukemias.Genomics. 1998 Oct 15;53(2):184-90. doi: 10.1006/geno.1998.5473.
• [81] The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma.Int J Mol Sci. 2017 Jun 1;18(6):1175. doi: 10.3390/ijms18061175.
• [82] Aberrant expression of CKLF-like MARVEL transmembrane member 5 (CMTM5) by promoter methylation in myeloid leukemia.Leuk Res. 2011 Jun;35(6):771-6. doi: 10.1016/j.leukres.2010.11.023. Epub 2010 Dec 18.
• [83] Expression of serologically identified tumor antigens in acute leukemias.Leuk Res. 2003 Jul;27(7):655-60. doi: 10.1016/s0145-2126(02)00230-8.
• [84] Regulation of HOXA9 activity by predominant expression of DACH1 against C/EBP and GATA-1 in myeloid leukemia with MLL-AF9.Biochem Biophys Res Commun. 2012 Sep 28;426(3):299-305. doi: 10.1016/j.bbrc.2012.08.048. Epub 2012 Aug 17.
• [85] Molecular cytogenetic analysis of complex karyotypes with derivative chromosome der(1)t(1;5) found in two patients with myeloid leukemia.Cancer Genet Cytogenet. 2007 Jul 15;176(2):150-5. doi: 10.1016/j.cancergencyto.2007.05.001.
• [86] Overexpression of the dual-specificity MAPK phosphatase PYST2 in acute leukemia.Cancer Lett. 2003 Sep 25;199(2):185-92. doi: 10.1016/s0304-3835(03)00352-5.
• [87] miR-139-5p controls translation in myeloid leukemia through EIF4G2.Oncogene. 2016 Apr 7;35(14):1822-31. doi: 10.1038/onc.2015.247. Epub 2015 Jul 13.
• [88] Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemia.Blood. 2013 Oct 10;122(15):2694-703. doi: 10.1182/blood-2013-01-477133. Epub 2013 Aug 23.
• [89] Leukemia patient-derived lymphoblastoid cell lines exhibit increased induction of leukemia-associated transcripts following high-dose irradiation.Exp Hematol. 1999 Sep;27(9):1397-401. doi: 10.1016/s0301-472x(99)00082-x.
• [90] Recurrent translocation t(10;17)(p15;q21) in minimally differentiated acute myeloid leukemia results in ZMYND11/MBTD1 fusion.Genes Chromosomes Cancer. 2016 Mar;55(3):237-41. doi: 10.1002/gcc.22326. Epub 2015 Nov 26.
• [91] The Wilms tumor protein is persistently associated with the nuclear matrix throughout the cell cycle.Mol Cell Biochem. 1997 Jun;171(1-2):121-6. doi: 10.1023/a:1006884527897.
• [92] Complete and long-lasting cytologic and molecular remission of FIP1L1-PDGFRA-positive acute eosinophil myeloid leukaemia, treated with low-dose imatinib monotherapy.Eur J Haematol. 2014 Jun;92(6):541-5. doi: 10.1111/ejh.12272. Epub 2014 Feb 19.
• [93] A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1.Cancer Discov. 2019 Jul;9(7):962-979. doi: 10.1158/2159-8290.CD-18-1391. Epub 2019 May 8.
• [94] The transcriptional regulator FUBP1 influences disease outcome in murine and human myeloid leukemia.Leukemia. 2019 Jul;33(7):1700-1712. doi: 10.1038/s41375-018-0358-8. Epub 2019 Jan 11.
• [95] Spectrum of myeloid neoplasms and immune deficiency associated with germline GATA2 mutations.Cancer Med. 2015 Apr;4(4):490-9. doi: 10.1002/cam4.384. Epub 2015 Jan 26.
• [96] Growth factor independent 1b (Gfi1b) and a new splice variant of Gfi1b are highly expressed in patients with acute and chronic leukemia.Int J Hematol. 2009 May;89(4):422-430. doi: 10.1007/s12185-009-0286-5. Epub 2009 Apr 10.
• [97] Induction of leukemia cell differentiation and apoptosis by recombinant P48, a modulin derived from Mycoplasma fermentans.Biochem Biophys Res Commun. 2000 Mar 5;269(1):284-9. doi: 10.1006/bbrc.2000.2282.
• [98] 5-Aminolevulinate synthase expression and hemoglobin synthesis in a human myelogenous leukemia cell line.J Biochem. 1997 Mar;121(3):487-95. doi: 10.1093/oxfordjournals.jbchem.a021613.
• [99] Differentiation and cell-type-restricted expression of HOXC4, HOXC5 and HOXC6 in myeloid leukemias and normal myeloid cells.Leukemia. 1998 Nov;12(11):1724-32. doi: 10.1038/sj.leu.2401106.
• [100] A novel nuclear protein, 5qNCA (LOC51780) is a candidate for the myeloid leukemia tumor suppressor gene on chromosome 5 band q31.Oncogene. 2001 Oct 18;20(47):6946-54. doi: 10.1038/sj.onc.1204850.
• [101] cDNA cloning, expression pattern, genomic structure and chromosomal location of RAB6KIFL, a human kinesin-like gene.Gene. 2000 May 2;248(1-2):117-25. doi: 10.1016/s0378-1119(00)00135-9.
• [102] Structural integrity and expression of the L3MBTL gene in normal and malignant hematopoietic cells.Genes Chromosomes Cancer. 2004 Nov;41(3):203-13. doi: 10.1002/gcc.20087.
• [103] Optical computed tomography for spatially isotropic four-dimensional imaging of live single cells.Sci Adv. 2017 Dec 6;3(12):e1602580. doi: 10.1126/sciadv.1602580. eCollection 2017 Dec.
• [104] Cooperating cancer-gene identification through oncogenic-retrovirus-induced insertional mutagenesis.Blood. 2005 Oct 1;106(7):2498-505. doi: 10.1182/blood-2004-12-4840. Epub 2005 Jun 16.
• [105] The oncogenic capacity of HRX-ENL requires the transcriptional transactivation activity of ENL and the DNA binding motifs of HRX.Mol Cell Biol. 1998 Jan;18(1):122-9. doi: 10.1128/MCB.18.1.122.
• [106] MN1, a novel player in human AML.Blood Cells Mol Dis. 2007 Nov-Dec;39(3):336-9. doi: 10.1016/j.bcmd.2007.06.009. Epub 2007 Aug 14.
• [107] High incidence of t(7;12)(q36;p13) in infant AML but not in infant ALL, with a dismal outcome and ectopic expression of HLXB9.Genes Chromosomes Cancer. 2006 Aug;45(8):731-9. doi: 10.1002/gcc.20335.
• [108] Identification in several human myeloid leukemias or cell lines of a DNA rearrangement next to the c-mos 3'-end.FEBS Lett. 1985 Sep 9;189(1):97-101. doi: 10.1016/0014-5793(85)80850-4.
• [109] c-Myc overcomes cell cycle inhibition by CBFbeta-SMMHC, a myeloid leukemia oncoprotein.Cancer Biol Ther. 2002 Sep-Oct;1(5):492-6. doi: 10.4161/cbt.1.5.163.
• [110] Myeloid leukemias express a broad spectrum of VEGF receptors including neuropilin-1 (NRP-1) and NRP-2.Leuk Lymphoma. 2007 Oct;48(10):1997-2007. doi: 10.1080/10428190701534424.
• [111] t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients.Haematologica. 2014 May;99(5):865-72. doi: 10.3324/haematol.2013.098517. Epub 2014 Jan 17.
• [112] Mutation analysis of the origin recognition complex subunit 5 (ORC5L) gene in adult patients with myeloid leukemias exhibiting deletions of chromosome band 7q22.Hum Genet. 2001 Apr;108(4):304-9. doi: 10.1007/s004390100498.
• [113] 19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia. Cancer Res. 2005 Mar 15;65(6):2488-97.
• [114] Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells.Exp Hematol. 2004 Jun;32(6):526-35. doi: 10.1016/j.exphem.2004.03.005.
• [115] Activation of clg, a novel dbl family guanine nucleotide exchange factor gene, by proviral insertion at evi24, a common integration site in B cell and myeloid leukemias.J Biol Chem. 2002 Apr 19;277(16):13463-72. doi: 10.1074/jbc.M110981200. Epub 2002 Feb 11.
• [116] Role of MmTRA1b/phospholipid scramblase1 gene expression in the induction of differentiation of human myeloid leukemia cells into granulocytes.Exp Hematol. 2002 May;30(5):421-9. doi: 10.1016/s0301-472x(02)00779-8.
• [117] Protein kinase D2 mediates activation of nuclear factor kappaB by Bcr-Abl in Bcr-Abl+ human myeloid leukemia cells.Cancer Res. 2004 Dec 15;64(24):8939-44. doi: 10.1158/0008-5472.CAN-04-0981.
• [118] Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms.Nat Genet. 2013 Oct;45(10):1232-7. doi: 10.1038/ng.2731. Epub 2013 Aug 18.
• [119] The role of decreased retinoblastoma protein expression in acute myelomonocytic and monoblastic leukemias.Leuk Lymphoma. 1995 Mar;17(1-2):135-7. doi: 10.3109/10428199509051713.
• [120] The SKI proto-oncogene enhances the in vivo repopulation of hematopoietic stem cells and causes myeloproliferative disease.Haematologica. 2014 Apr;99(4):647-55. doi: 10.3324/haematol.2013.093971. Epub 2014 Jan 10.
• [121] PRL-3 exerts oncogenic functions in myeloid leukemia cells via aberrant dephosphorylation of stathmin and activation of STAT3 signaling.Aging (Albany NY). 2019 Sep 23;11(18):7817-7829. doi: 10.18632/aging.102290. Epub 2019 Sep 23.
• [122] Stat1 is induced and activated by all-trans retinoic acid in acute promyelocytic leukemia cells.Blood. 1997 Feb 1;89(3):1001-12.
• [123] Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells.Nat Genet. 2017 Jun;49(6):866-875. doi: 10.1038/ng.3854. Epub 2017 Apr 24.
• [124] Association of MDR1 G2677T polymorphism and leukemia risk: evidence from a meta-analysis.Tumour Biol. 2014 Mar;35(3):2191-7. doi: 10.1007/s13277-013-1291-0. Epub 2013 Oct 20.
• [125] TLE4 regulation of wnt-mediated inflammation underlies its role as a tumor suppressor in myeloid leukemia.Leuk Res. 2016 Sep;48:46-56. doi: 10.1016/j.leukres.2016.07.002. Epub 2016 Jul 21.
• [126] Basophils (Bsp-1+) derive from the leukemic clone in human myeloid leukemias involving the chromosome breakpoint 9q34.Blood. 1989 Feb 15;73(3):777-81.
• [127] The N(6)-methyladenosine (m(6)A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells.Nat Med. 2017 Nov;23(11):1369-1376. doi: 10.1038/nm.4416. Epub 2017 Sep 18.
• [128] COUP-TFII is a modulator of cell-type-specific genetic programs based on genomic localization maps.J Biotechnol. 2019 Aug 10;301:11-17. doi: 10.1016/j.jbiotec.2019.05.305. Epub 2019 May 31.
• [129] Chromatin-remodeling factor SMARCD2 regulates transcriptional networks controlling differentiation of neutrophil granulocytes. Nat Genet. 2017 May;49(5):742-752. doi: 10.1038/ng.3833. Epub 2017 Apr 3.